Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 191 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Standard of care only Clear all
Completed Phase 4 Interventional Results available

A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion

NCT02424591
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 11:57 AM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

NCT04331899
View directory record Official record
Conditions
COVID-19
Interventions
Peginterferon Lambda-1a, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 8, 2026, 11:57 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Incrediwear Products Immediately After ACL Repair

NCT06668376
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear, Medial Collateral Ligament
Interventions
Leg Sleeve, Placebo
Device
Lead sponsor
Texas Bone and Joint
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 8, 2026, 11:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

NCT04069195
View directory record Official record
Conditions
Inflammation, Pregnancy Related
Interventions
DHA supplement, Corn Oil: Soybean Oil
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy

NCT00624910
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine Collagen Sponge (CollaRx®), placebo
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

NCT00066066
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline
Procedure · Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
20 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 4 Interventional

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Active, not recruiting Not applicable Interventional

Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation

NCT05351333
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burns
Interventions
placebo
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

APX005M and Doxorubicin in Advanced Sarcoma

NCT03719430
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxorubicin, APX005M
Drug
Lead sponsor
Alexander Z. Wei, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Not applicable Interventional Results available

Educational-Medical-Behavioral Treatment of Fecal Incontinence

NCT01717456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 8, 2026, 11:57 AM EDT
Not yet recruiting Phase 4 Interventional

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

NCT07387315
View directory record Official record
Conditions
Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder Neurogenesis, Urinary Incontinence, Urge, Pelvic Floor Disorders
Interventions
Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Withdrawn Phase 2 Interventional

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

NCT05701189
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
Drug
Lead sponsor
Chafic Karam
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 8, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 8, 2026, 11:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

NCT00958776
View directory record Official record
Conditions
Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
Interventions
Peramivir+SOC, Placebo+SOC
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
60
States / cities
La Mesa, California • Long Beach, California • Modesto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 8, 2026, 11:57 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 8, 2026, 11:57 AM EDT